Resiniferatoxin

Generic Name: Resiniferatoxin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₇H_₄₀O_₉

CAS Number: 57444-62-9

Unique Ingredient Identifier: A5O6P1UL4I

Background: Resiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission of physiological pain).

Indication: Investigated for use/treatment in interstitial cystitis and urinary incontinence.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Resiniferatoxin for the Management of Refractory Morton s Neuroma Pain

Phase 1

Recruiting

Conditions: Morton's Neuroma

Interventions: Drug: Resiniferatoxin

First Posted Date: 2023-01-25

Last Posted Date: 2024-12-20

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 24

Registration Number: NCT05695339

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Phase 2

Suspended

Conditions: Pain Cancer
Pain, Intractable
Pain

Interventions: Drug: Placebo
Drug: Resiniferatoxin

First Posted Date: 2021-10-05

Last Posted Date: 2024-03-18

Lead Sponsor: Sorrento Therapeutics, Inc.

Target Recruit Count: 120

Registration Number: NCT05067257

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸
Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California, United States

and more 1 locations

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

Phase 2

Active, not recruiting

Conditions: Osteoarthritis, Knee
Knee Osteoarthritis
Knee Pain Chronic

Interventions: Drug: Resiniferatoxin
Drug: Placebo
Drug: Zilretta

First Posted Date: 2021-05-13

Last Posted Date: 2023-01-17

Lead Sponsor: Sorrento Therapeutics, Inc.

Target Recruit Count: 124

Registration Number: NCT04885972

Locations: 🇺🇸
HD Research LLC, Carrollton, Texas, United States
🇺🇸
Horizon Clinical Research, La Mesa, California, United States
🇺🇸
Advance Pain, Edgewood, Kentucky, United States

and more 2 locations

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Phase 3

Withdrawn

Conditions: Pain, Intractable
Pain Cancer

Interventions: Other: Standard of Care
Drug: Resiniferatoxin

First Posted Date: 2020-10-01

Last Posted Date: 2021-11-09

Lead Sponsor: Sorrento Therapeutics, Inc.

Registration Number: NCT04572776

Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed

Phase 3

Withdrawn

Conditions: Osteoarthritis, Knee
Knee Pain Chronic
Osteo Arthritis Knee

Interventions: Drug: Resiniferatoxin
Drug: Placebo

First Posted Date: 2020-05-13

Last Posted Date: 2021-11-09

Lead Sponsor: Sorrento Therapeutics, Inc.

Registration Number: NCT04386980

A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee

Phase 3

Withdrawn

Conditions: Osteoarthritis, Knee
Knee Pain Chronic

Interventions: Drug: Resiniferatoxin
Drug: Placebo

First Posted Date: 2019-08-05

Last Posted Date: 2021-11-09

Lead Sponsor: Sorrento Therapeutics, Inc.

Registration Number: NCT04044742

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

Phase 1

Completed

Conditions: Osteoarthritis, Knee
Pain, Knee

Interventions: Drug: Resiniferatoxin
Drug: Saline

First Posted Date: 2018-05-31

Last Posted Date: 2021-04-01

Lead Sponsor: Sorrento Therapeutics, Inc.

Target Recruit Count: 94

Registration Number: NCT03542838

Locations: 🇺🇸
Snibbe Orthopedics, Los Angeles, California, United States
🇺🇸
University of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

and more 1 locations

Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain

Phase 1

Completed

Conditions: Intractable Cancer Pain

Interventions: Drug: Resiniferatoxin

First Posted Date: 2017-07-24

Last Posted Date: 2020-10-20

Lead Sponsor: Sorrento Therapeutics, Inc.

Target Recruit Count: 17

Registration Number: NCT03226574

Locations: 🇺🇸
University of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Hermann Drive Surgical Hospital, Houston, Texas, United States
🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

and more 1 locations

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

Phase 1

Not yet recruiting

Conditions: Palliative Care
Intractable Pain

Interventions: Drug: Resiniferatoxin

First Posted Date: 2015-08-13

Last Posted Date: 2024-12-17

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 30

Registration Number: NCT02522611

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy